A Peptidomic Analysis of the Potential Comorbidity Biomarkers for Type 2 Diabetes Mellitus and Alzheimer’s Disease

Zhengqiang Du, Jian Hua, Xu Su, Dalin Song*

Department of General Medicine, Qingdao Municipal Hospital, Qingdao, China
Email: *billy_mei@126.com

Abstract

Objective: To investigate the potential comorbidity biomarkers for Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s disease (AD). Methods: This is a randomized case-control study. There are three groups: 1) normal control group included 32 healthy elderly people in the hospital physical examination; 2) 30 patients with T2DM group; and 3) AD group has 28 cases. On-line reversed-phase liquid chromatography separation, tandem mass spectrometry analysis and iTRAQ quantification were used for identification of peptidomic analysis, then detection of three comorbidity biomarkers might be associated with T2DM and AD by ELISA. Results: The Peptidomic Analysis of the potential comorbidity biomarkers for T2DM and the AD group includes Osteopontin (OPN), Isoform 2 of Histone H2Btype 2-F and Histone H4. These potential comorbidity biomarkers for T2DM and the AD group are significantly increased than normal control group. OPN concentrations are 1.67 (0.13 - 2.63) mmol/L in the normal control group, 3.15 (1.51 - 5.35) mmol/L in the T2DM group, and 7.66 (3.55 - 15.38) mmol/L in the AD group. Histone H4 concentrations in three groups respectively are 0.21 ± 0.036 mmol/L (normal control), 0.21 ± 0.046 mmol/L (T2DM) and 0.21 ± 0.034 mmol/L(AD). Isoforms 2 of Histone H2Btype 2-F are 1.73 (0.12 - 2.60) mmol/L, 4.71 (1.26 - 6.84) mmol/L and 9.30 (0 - 20.8) mmol/L in three groups respectively. Conclusion: The inflammatory mechanism may lead to an increase of histone content in the urine of AD and T2DM patients. Clinical test of these potential comorbidity biomarkers Histones and Osteopontin would be the diagnosis of comorbidity AD and T2DM.

Keywords

Type 2 Diabetes Mellitus (T2DM), Alzheimer’s Disease (AD), Comorbidity Biomarkers, Osteopontin, Histones
1. Introduction

Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s disease (AD) are consistent in many aspects, which provide a theoretical basis for the correlation between them. There are some mainly manifested in the following aspects that not only highly correlated with the occurrence of T2DM, but also seem to affect the occurrence and development of AD: 1) Risk factors: such as genetic factors, advanced age, high-fat diet, obesity and lack of exercise, etc. [1] [2]. 2) Pathogenesis: insulin resistance, toxic effects of high glucose, oxidative stress, inflammatory reaction, hypercholesterolemia, mitochondrial dysfunction [3]-[11]. 3) Pathological features: AD and T2DM patients have specific insoluble polymer deposition in their bodies. Amyloidβ-protein (Aβ) deposits were found in the brain of patients with AD, and abnormal deposition of Aβ was found in islet beta cells of patients with T2DM, suggesting that Aβ was formed by unnatural folding and aggregation of the homologous protein—Islet amyloid polypeptide (IAPP) [12] [13]. 4) Treatment: long-acting insulin analogues (LAIA) of Glucagon-like peptide-1 (GLP-1) have been widely used in clinical practice as a novel drug for the treatment of T2DM. In recent years, GLP-1 and its analogues have been proved to improve the cognitive function of AD model mice [14]. So far, there are no studies to reveal potential comorbidity biomarkers for T2DM and AD. This research was used to analyze peptides spectrum of the urine within T2DM and AD patients by Mass Spectrometry, as well as explore the mechanism of comorbidity.

2. Materials and Methods

2.1. Objectors

This is a randomized case-control study, and has been approved by the hospital ethics committee since 2015. All samples signed the informed consent and are divided into three groups: 1) normal control group included 32 healthy elderly people in the hospital physical examination; 2) 30 patients with T2DM group; and 3) AD group has 28 cases. All patients are admitted to the Geriatric department of Qingdao municipal hospital. Exclusion criteria: hypertension, coronary heart disease, stroke, cerebrovascular disease, head trauma, Parkinson’s syndrome. The patients in T2DM group had no cognitive impairment or depression T2DM group complication, as well as AD patients have been clearly diagnosed without diabetes mellitus.

2.2. Sample Preparation

The venous plasma and urine samples are collected in the morning when all subjects were on an empty stomach. Using sterilized bottles with 5 - 10 ml urine, the samples are stored in the −80°C refrigerator within two hours for later use. Enrichment of peptides in the urine of 1) will be saved out of A healthy person’s urine specimen, thaw at room temperature, in 4°C, under the condition of 12,000 RPM centrifuge for 10 min after absorbing supernatant in another clean
EP tube, notes for A; 2) add the aqueous dispersion of lanthanum-grapheme magnetic material into A at the ratio of urine:material = 50:1, and vortex at 2000 rpm/min for 10 min; Centrifuge at 1000 rpm for 5 min, and take the precipitate, denoted as B; 3) 500 μl water was added to B, vortex at 1000 rpm/min for 10 min, centrifuge at 1000 rpm for 5 min, and the supernatant was discarded from the obtained samples. The corresponding precipitation was repeated for 2 times, and the final sample was recorded as C; 4) add 20 μl eluent to C, vortex at 2000 rpm/min for 10 min, centrifuge at 1000 rpm for 10 min, and transfer the supernatant to another EP tube, denoted as D; 5) centrifuge D at 12,000 rpm for 10 min, discard supernatant, seal with sealing film, bind a considerable number of holes in the sealing film, and freeze dry the specimen in vacuum freeze-dryer, denoted as E.

2.3. On-Line Reversed-Phase Liquid Chromatography Separation and Tandem Mass Spectrometry Analysis

Equipment and materials: Centrifuge; Oscillator; Aqueous dispersion of lanthanum-grapheme magnetic materials: (30 mg/ml); Vacuum freeze dryer; Eluent: 80%ACN containing 1%TFA; Liquid chromatography liquid A (0.1% formic acid/2% acetonitrile/98% aqueous solution); B solution (0.1% formic acid/2% water/98% acetonitrile solution); Analysis column: 75 m × 15 cm, c18-3 m 120 A; Column: 3 m, 120 A; EksigentnanoLC-Ultra™ 2d performance liquid chromatography (HPLC)-TripleTOF 5600 mass spectrometry instrument; OLYMPUS au1000/2700 automatic biochemical analyzer.

Sample E was dissolved in a solution of 0.1% formic acid/2% acetonitrile/98%. The sample was loaded at about 2 μg on the Nano liter flow column, desalted in liquid A for 10 min, then elution was carried out in liquid B, and the sample was scanned by mass spectrometry.

2.4. Database Search and iTRAQ Quantification

The raw peptides, protein identification and quantification were performed using ProteinPilot v4.5 (AB Sciex) with the Paragon Algorithm against the UniProt “complete proteome” human proteins database. To reduce false positive identification results, a minimum unused score of 1.3 (equivalent to 95% confidence) and false discovery rate (FDR) less than 1% were required for all reported proteins. At least one unique peptide per protein group was required for identification of proteins, while two quantified peptides were required for quantification of proteins. Based on a 95% confidence level, cutoff values of 1.5-fold for unregulated proteins and of 0.67-fold for downregulated proteins were used to identify differentially expressed proteins between the patients and healthy controls [15].

2.5. Detection of Three Comorbidity Biomarkers Might Be Associated with T2DM and AD by ELISA

The decrease levels of osteopontin (OPN) and Histone H4 were detected in the
serum of T2DM and AD patients compared with that of healthy controls. OPN ELISA kit is R&D Systems, and Human Histone H4 and Histone H2B type 2 ELISA kits are Cusabio.

2.6. Statistical Calculation

PASW Statistics 18 software was used to establish database and statistical analysis; mean standard deviation was used for parameter continuous variables; t test was used for two groups; Nonparametric continuous variables were expressed as median (minimum - maximum), and paired q test was used for the two groups. Variance analysis was used to compare continuous variables among groups. The rate comparison was conducted by Fisher’s exact test. P < 0.05 was considered statistically significant.

3. Results

3.1. Basic Clinical Parameter

There were significant differences in blood glucose levels between the T2DM group and the control group, and between the T2DM group and the AD group (P = 0.017). There was no statistically significant difference in blood glucose levels between the control group and the AD group (Table 1).

3.2. The Peptidomic Analysis of the Potential Comorbidity Biomarker

816 polypeptides corresponding to 100 proteins were detected in the urine of patients with T2DM. We were successfully identified, out of which 279 and 386 serum proteins were identified in AD. A total of 1048 peptides corresponding to 133 proteins were detected in normal urine. The contents and types of polypeptides in urine of the two groups were different, and the corresponding proteins were also different. Table 2 shows the protein types and amounts corresponding to the top 10 peptides in urine of the three groups. The Peptidomic Analysis of the potential comorbidity biomarkers for T2DM and the AD group include: Osteopontin, Isoform 2 of Histone H2Btype 2-F and Histone H4 (Table 2 and Figure 1 and Figure 2).

3.3. Comparison of These Potential Comorbidity Biomarkers for among Three Groups

OPN concentration are 1.67 (0.13 - 2.63) mmol/L in the normal control group, 3.15 (1.51 - 5.35) mmol/L in the T2DM group, and 7.66 (3.55 - 15.38) mmol/L in the AD group. Histone H4 concentration in three groups respectively are 0.21 ± 0.036 mmol/L (normal control), 0.21 ± 0.046 mmol/L (T2DM) and 0.21 ± 0.034 mmol/L (AD). Isoform 2 of Histone H2Btype 2-F are 1.73 (0.12 - 2.60) mmol/L, 4.71 (1.26 - 6.84) mmol/L and 9.30 (0 - 20.8) mmol/L in three groups respectively. These potential comorbidity biomarkers for T2DM and the AD group are significantly increased than normal control group (Figure 3).
Figure 1. Urine sample markers of the polypeptide group detection by mass spectrometry.

Figure 2. The peptidomic analysis of the potential comorbidity biomarkers for T2DM and the AD group.

Figure 3. Comparison of these potential comorbidity biomarkers for among three groups.
Table 1. Comparison of clinical parameters among the three groups.

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>Normal control (n = 32)</th>
<th>T2DM (n = 30)</th>
<th>AD (n = 28)</th>
<th>F/H</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (x ± sy)</td>
<td>70.14 ± 14.14</td>
<td>71.90 ± 7.12</td>
<td>71.20 ± 8.35</td>
<td>2.11</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>M/F (case)</td>
<td>17/15</td>
<td>18/12</td>
<td>15/13</td>
<td>1.05</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.00 (19.9 - 28.1)</td>
<td>24.85 (21.3 - 28.4)</td>
<td>23.5 (19.0 - 28.0)</td>
<td>1.21</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>131 (122 - 140)</td>
<td>136 (122 - 150)</td>
<td>131 (120 - 142)</td>
<td>0.24</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>77.5 (65 - 90)</td>
<td>80.0 (65 - 95)</td>
<td>79.0 (63 - 95)</td>
<td>0.67</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.34 ± 0.87</td>
<td>1.87 ± 0.38</td>
<td>1.40 ± 0.74</td>
<td>1.82</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.35 ± 0.07</td>
<td>1.21 ± 0.06</td>
<td>1.16 ± 0.08</td>
<td>1.66</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>4.03 ± 0.69</td>
<td>3.62 ± 0.82</td>
<td>4.12 ± 0.65</td>
<td>2.45</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>FPG (mmol/L)</td>
<td>5.97 ± 0.73</td>
<td>8.9 ± 0.79</td>
<td>6.57 ± 0.81</td>
<td>7.08</td>
<td>&lt;0.05*</td>
</tr>
</tbody>
</table>

F/H: Fisher’s exact test/H.

Table 2. Top 10 peptides in urine of three groups.

<table>
<thead>
<tr>
<th>No</th>
<th>Normal control</th>
<th>T2DM</th>
<th>AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Alpha-1-antitrypsin</td>
<td>Alpha-1-antitrypsin</td>
<td>Isoform 2 of Histone H2B type 2-F</td>
</tr>
<tr>
<td>2</td>
<td>Leucine-rich alpha-2-glycoprotein</td>
<td>Transthyretin</td>
<td>Actin</td>
</tr>
<tr>
<td>3</td>
<td>Hemoglobin subunit beta</td>
<td>Hemoglobin subunit alpha</td>
<td>Osteopontin</td>
</tr>
<tr>
<td>4</td>
<td>Angiotensinogen</td>
<td>Hemoglobin subunit β</td>
<td>Human Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4)</td>
</tr>
<tr>
<td>5</td>
<td>Plasma protease C1 inhibitor</td>
<td>Apolipoprotein A-I</td>
<td>Histone H4</td>
</tr>
<tr>
<td>6</td>
<td>Hemoglobin subunit alpha</td>
<td>Osteopontin</td>
<td>Histone H2A</td>
</tr>
<tr>
<td>7</td>
<td>HP protein</td>
<td>Apolipoprotein A-IV</td>
<td>β-2 microglobulin,</td>
</tr>
<tr>
<td>8</td>
<td>Carbonic anhydrase 1</td>
<td>Complement C3</td>
<td>Glyceraldehyde-3-phosphate dehydrogenase (GAPD)</td>
</tr>
<tr>
<td>9</td>
<td>Uromodulin</td>
<td>Isoform 2 of Histone H2B type 2-F</td>
<td>Ceruloplasmin (CER)</td>
</tr>
<tr>
<td>10</td>
<td>Isoform 2 of Prostatic acid phosphatase</td>
<td>Histone H4</td>
<td>trypsin inhibitor H4</td>
</tr>
</tbody>
</table>

4. Discussion

These results demonstrate that Histones and Osteopontin may be involved in the pathogenesis of AD patients and T2DM patients, and the inflammatory mechanism may lead to the increase of histone content in the urine of AD and T2DM patients. Clinical test of these potential comorbidity biomarkers would be the diagnosis of comorbidity AD and T2DM.

There are 5 subtypes of histones, namely histone H1, histone H2A, histone H2B, histone H3 and histone H4. In this experiment, the contents of histone
H2B, histone H2A and histone H4 in the urine of AD patients and T2DM patients were significantly increased. The main role of histones is to participate in the formation of nucleosomes and maintain the stability of chromosome structure. However, the role of histones is increasingly recognized with the development of research with developing research. Silva et al. [16] revealed that histones are closely related to learning and memory. This study showed that the acetylation of histones can activate the transcription of genes related to learning and memory formation, increase the formation of synapses, and thus promote the process of learning and memory. Histone acetylation is regulated by both acetylase and deacetylase. Studies have shown that the expression of histone deacetylases (HDACs) in the brain of patients with AD is increased, and the level of white acetylases in group b is decreased [17]. On the other hand, HDAC6 in the cytoplasmic nucleus could regulate the phosphorylation process of Tau protein by interacting, and further form fiber tangles to participate in the pathogenesis of AD [18]. In addition, histones are also involved in inflammatory reactions through the nlrp3 pathway, and inflammatory cytokines are released and neutrophils are recruited [19]. Friggeri et al. [20] confirmed that both histone H3 and H4 could weaken the uptake and clearance of mononuclear phagocytes to apoptotic cells in vivo and in vitro experiments, thus enhancing the inflammatory response. Pemberton et al. [21] found that histone can make low-density lipoprotein deposit in the blood vessels, which may be the early change of atherosclerosis. This finding may provide a new way to explain vascular diseases in DM patients.

Some experiments aimed at exploring whether OPN was related to T2DM complications. Genomics studies have shown that increased OPN level in different diabetic nephropathy models is closely related to severe DN proteinuria [22]. Another study pointed out that plasma OPN level was positively correlated with DN, and no evidence was found that plasma OPN level was correlated with DM retinopathy and neuropathy [23]. Transient proteinuria was observed in 6 weeks old male mice 24 h after LPS injection. After dissection, kidney lysates were taken from the mice in this group, and quantitative real-time PCR analysis showed that the level of OPN mRNA was significantly increased. For answer the question of whether OPN plays a role in the development of proteinuria, the researchers treated mice with gene knockout technology and found that no significant proteinuria was found in the OPN gene knockout mice 24 hours after the injection of bacterial LPS compared with the wild-type mice. Thus, it was speculated that OPN was involved in the formation of proteinuria [24]. Later, Nicholas et al. [25] showed that the excretion rate of urinary protein in OPN gene knockout mice decreased significantly.

As 6-month-old APP/PS1KI model mice have axonal degeneration, neuron loss and memory loss, they are often used in relevant studies on AD. Some data demonstrated that the OPN in the brain of 6-month-old APP/PS1KI model mice was 2.8 times that of 2-month-old mice (P = 0.01), and the immunohistochemical staining with the anti-mouse OPN antibody showed enhanced brain reactiv-
ity. After staining with A and OPN double antibodies, it was found that the mouse axon antibody was significantly deposited [26]. Clinical studies have shown that the content of OPN in cerebrospinal fluid of AD patients is higher than that of mild cognitive impairment (MCI). This study points out that OPN could be used as an indicator to predict whether MCI patients progress to AD [27].

At present, the levels of histone and OPN in AD patients are still controversial at home and abroad, and the specific mechanism is conversely being explored. Our study has several limitations. First, the small sample size prevented us from extrapolating the results to all T2DM populations. Secondly, patients with MCI were not included, and relevant data of such population were lacking. Finally, the inclusive statistics did not include glycosylated hemoglobin, which could not well reflect the effect of blood glucose fluctuations on the test results. Therefore, it is reasonable to increase the sample size and different categories, and improve the extensive examination indicators (such as HbA1c).

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References


Mouse Kidney Reveals Novel Genes Linked to Glomerular Disease. *Diabetes*, **53**, 784-794. [https://doi.org/10.2337/diabetes.53.3.784](https://doi.org/10.2337/diabetes.53.3.784)


